Description

A180^® is a sterile solution containing danofloxacin mesylate, a synthetic fluoroquinolone antimicrobial agent.

Approved Uses

A180 (danofloxacin) injectable solution is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia (Pasteurella) haemolytica and Pasteurella multocida.

Key Features

• Proven BRD Treatment Success. When used in the recommended treatment program, A180 has been proven effective against even severe cases of BRD¹.



• A180 rapidly concentrates in diseased lung tissue to fight BRD bacterial infections fast^1,2.



• A180 provides broad-spectrum control of the most common and costly BRD bacterial pathogens³.



• Two 1.5-mL/100-lbs. doses at 48-hour intervals yielded 87% cure rates in controlled field efficacy trials—even in severe cases of BRD¹.



• A180 is a bactericidal concentration-dependent killing (CDK) product. CDK products are most effective when the drug concentration in blood and lung tissue exceeds the MIC (minimum inhibitory concentration) of the target bacteria.



• A180 has been demonstrated to achieve peak concentration in infected lung tissue one hour after treatment – that’s more than three times greater than Baytril (enrofloxacin)⁴.



• Low Dosage and Short Withdrawal.



• A180’s low volume dosage and short withdrawal period deliver unmatched convenience and flexibility.



• A180’s 4-day withdrawal gives producers the flexibility to treat even heavyweight cattle.



• When used as directed, A180 does not present a significant risk to the environment or those administering the drug¹.



• An Excellent Overall Value. Dose for dose A180 is an economical approach to BRD therapy.

• The effects of danofloxacin on bovine reproductive performance, pregnancy, and lactation have not been determined.



• Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.



• Quinolone-class drugs should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation, which may lead to convulsive seizures.



• Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature, rapidly growing animals of various species. Refer to Animal Safety for information specific to danofloxacin.
  
  
• Federal law restricts this drug to use by or on the order of a licensed veterinarian.



• Federal law prohibits the extra label use of this product in food producing animals.